A Double-Blind, Randomised, Placebo Controlled Phase I Study to assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Ascending Doses of BioE-1115 in Healthy Adult Volunteers
Latest Information Update: 25 Feb 2020
At a glance
- Drugs BioE 1115 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; First in man
Most Recent Events
- 21 Feb 2020 Status changed from not yet recruiting to discontinued.
- 22 Mar 2019 New trial record